# Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Source: https://onco.cc/trials/nct03778229/  
OnCo record `nct03778229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib is a phase 2 interventional study registered as NCT03778229 by AstraZeneca, with 367 participants enrolled, started 2019-01-09 and due to reach its primary completion in 2024-08-23. Interventions recorded: osimertinib, savolitinib and placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: SAVANNAH
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03778229
- Phase: 2
- Setting: A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
- Sponsor: AstraZeneca
- Enrolled: 367
- Outcomes: Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set: Savo 300 mg BID + Osi 56.3%; Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set: Savo 300 mg QD + Osi 31.6%; Overall Survival (OS); Target Population Analysis Set: Savo 300 mg BID + Osi 14.42 months

## Sources

- ClinicalTrials.gov NCT03778229: https://clinicaltrials.gov/study/NCT03778229

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Hutchmed](https://onco.cc/companies/hutchmed/)
- key papers: [Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study](https://onco.cc/key-papers/paper-nct03778229-ann-oncol-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct03778229.json